Outside AI, earnings momentum across emerging markets remains healthy, but the market is rewarding it unevenly.

Goldman Sachs Group (GS) has upgraded its three-month outlook on global equities to overweight from neutral, citing strong ...

Hims & Hers Health is rated a buy, with a fair value estimate of $41 per share versus the current $29.81. Read more on HIMS ...

Nokia (NOK) announced that it has signed a definitive agreement to sell its Enterprise Campus Edge ((ECE)) business to asset ...

BSOL is rated a speculative buy for long-term holders, leveraging both SOL appreciation and staking income. Read more on the ...

Stryker rebounded in 2Q26, with operating momentum restored after the prior quarter’s cybersecurity disruption. Learn why SYK ...

When bond traders start demanding higher interest rates in exchange for their money, as we have seen recently with 10-Year ...

Persistent Gulf disruption and a Federal Reserve pivot toward rate hikes kept resource markets volatile in Q3.

The Greenlight Capital funds returned -4.3% in Q2 2026 and 1.9% YTD, each net of fees and expenses. Read more here.

We added several new, small long positions during the quarter, such as Comcast, Fortune Brands Innovations, Primo Brands, ...

General Motors ( GM) CEO Mary Barra said Monday that the automaker remains on schedule to launch “eyes-off, hands-off” ...

Q4 FY26 record results, AI chip demand, and margin upside drive a Buy case. Read here for a detailed investment analysis.